{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:56:37Z","timestamp":1794513397015,"version":"4.9.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10430 01 201 0007"],"award-info":[{"award-number":["10430 01 201 0007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10430 01 201 0007"],"award-info":[{"award-number":["10430 01 201 0007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10430 01 201 0007"],"award-info":[{"award-number":["10430 01 201 0007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["101005142"],"award-info":[{"award-number":["101005142"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["101005142"],"award-info":[{"award-number":["101005142"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["101005142"],"award-info":[{"award-number":["101005142"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The pathobiology of respiratory failure in COVID-19 consists of a complex interplay between viral cytopathic effects and a dysregulated host immune response. In critically ill patients, imatinib treatment demonstrated potential for reducing invasive ventilation duration and mortality. Here, we perform longitudinal profiling of 6385 plasma proteins in 318 hospitalised patients to investigate the biological processes involved in critical COVID-19, and assess the effects of imatinib treatment. Nine proteins measured at hospital admission accurately predict critical illness development. Next to dysregulation of inflammation, critical illness is characterised by pathways involving cellular adhesion, extracellular matrix turnover and tissue remodelling. Imatinib treatment attenuates protein perturbations associated with inflammation and extracellular matrix turnover. These proteomic alterations are contextualised using external pulmonary RNA-sequencing data of deceased COVID-19 patients and imatinib-treated Syrian hamsters. Together, we show that alveolar capillary barrier disruption in critical COVID-19 is reflected in the plasma proteome, and is attenuated with imatinib treatment. This study comprises a secondary analysis of both clinical data and plasma samples derived from a clinical trial that was registered with the EU Clinical Trials Register (EudraCT 2020\u2013001236\u201310,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001236-10\/NL\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001236-10\/NL<\/jats:ext-link>\n                    ) and Netherlands Trial Register (NL8491,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.trialregister.nl\/trial\/8491\">https:\/\/www.trialregister.nl\/trial\/8491<\/jats:ext-link>\n                    ).\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-44986-w","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T08:02:29Z","timestamp":1706169749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-5578","authenticated-orcid":false,"given":"Erik","family":"Duijvelaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0511-8123","authenticated-orcid":false,"given":"Jack","family":"Gisby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-3440","authenticated-orcid":false,"given":"James E.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5371-0346","authenticated-orcid":false,"given":"Harm Jan","family":"Bogaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6211-1791","authenticated-orcid":false,"given":"Jurjan","family":"Aman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"44986_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1164\/rccm.202106-1514OC","volume":"205","author":"DE Leisman","year":"2022","unstructured":"Leisman, D. E. et al. Alveolar, endothelial, and organ injury marker dynamics in severe COVID-19. Am. J. Respir. Crit. Care Med. 205, 507\u2013519 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"44986_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/path.5642","volume":"254","author":"LE van Eijk","year":"2021","unstructured":"van Eijk, L. E. et al. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. J. Pathol. 254, 307\u2013331 (2021).","journal-title":"J. Pathol."},{"key":"44986_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","volume":"21","author":"A Bonaventura","year":"2021","unstructured":"Bonaventura, A. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 21, 319\u2013329 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"44986_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","volume":"9","author":"J Aman","year":"2021","unstructured":"Aman, J. et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir. Med. 9, 957\u2013968 (2021).","journal-title":"Lancet Respir. Med."},{"key":"44986_CR5","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/S2213-2600(22)00052-2","volume":"10","author":"E Duijvelaar","year":"2022","unstructured":"Duijvelaar, E. et al. Long-term clinical outcomes of COVID-19 patients treated with imatinib. Lancet Respir. Med. 10, e34\u2013e35 (2022).","journal-title":"Lancet Respir. Med."},{"key":"44986_CR6","doi-asserted-by":"publisher","unstructured":"de Brabander, J. et al. Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.00780-2022 (2022).","DOI":"10.1183\/13993003.00780-2022"},{"key":"44986_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41576-020-0268-2","volume":"22","author":"K Suhre","year":"2021","unstructured":"Suhre, K., McCarthy, M. I. & Schwenk, J. M. Genetics meets proteomics: perspectives for large population-based studies. Nat. Rev. Genet. 22, 19\u201337 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"44986_CR8","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1164\/rccm.202105-1302OC","volume":"204","author":"P Sinha","year":"2021","unstructured":"Sinha, P. et al. Latent class analysis reveals COVID-19-related acute respiratory distress syndrome subgroups with differential responses to corticosteroids. Am. J. Respir. Crit. Care Med. 204, 1274\u20131285 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"44986_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186\u2013193 (2022).","journal-title":"Nat. Immunol."},{"key":"44986_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21702-6","volume":"12","author":"P Bost","year":"2021","unstructured":"Bost, P. et al. Deciphering the state of immune silence in fatal COVID-19 patients. Nat. Commun. 12, 1428 (2021).","journal-title":"Nat. Commun."},{"key":"44986_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S2213-2600(21)00218-6","volume":"9","author":"MF Osuchowski","year":"2021","unstructured":"Osuchowski, M. F. et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet. Respir. Med. 9, 622\u2013642 (2021).","journal-title":"Lancet. Respir. Med."},{"key":"44986_CR12","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1182\/bloodadvances.2020003568","volume":"5","author":"ML Meizlish","year":"2021","unstructured":"Meizlish, M. L. et al. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Adv. 5, 1164\u20131177 (2021).","journal-title":"Blood Adv."},{"key":"44986_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cell.2020.05.032","volume":"182","author":"B Shen","year":"2020","unstructured":"Shen, B. et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell 182, 59\u201372.e15 (2020).","journal-title":"Cell"},{"key":"44986_CR14","unstructured":"SARS-CoV-2 innate immunity evasion and cell-specific immune response | WikiPathways. https:\/\/www.wikipathways.org\/pathways\/WP5039.html."},{"key":"44986_CR15","doi-asserted-by":"publisher","first-page":"eabj7790","DOI":"10.1126\/scitranslmed.abj7790","volume":"13","author":"F D\u2019Agnillo","year":"2021","unstructured":"D\u2019Agnillo, F. et al. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. Sci. Transl. Med. 13, eabj7790 (2021).","journal-title":"Sci. Transl. Med."},{"key":"44986_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41577-020-0343-0","volume":"20","author":"L-A Teuwen","year":"2020","unstructured":"Teuwen, L.-A., Geldhof, V., Pasut, A. & Carmeliet, P. COVID-19: the vasculature unleashed. Nat. Rev. Immunol. 20, 389\u2013391 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"44986_CR17","doi-asserted-by":"publisher","first-page":"100287","DOI":"10.1016\/j.xcrm.2021.100287","volume":"2","author":"MR Filbin","year":"2021","unstructured":"Filbin, M. R. et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep. Med. 2, 100287 (2021).","journal-title":"Cell Rep. Med."},{"key":"44986_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35454-4","volume":"13","author":"JS Gisby","year":"2022","unstructured":"Gisby, J. S. et al. Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence. Nat. Commun. 13, 7775 (2022).","journal-title":"Nat. Commun."},{"key":"44986_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4161\/cam.20167","volume":"6","author":"B Key","year":"2012","unstructured":"Key, B. & Lah, G. J. Repulsive guidance molecule A (RGMa): a molecule for all seasons. Cell Adh. Migr. 6, 85\u201390 (2012).","journal-title":"Cell Adh. Migr."},{"key":"44986_CR20","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1007\/s11010-021-04216-z","volume":"476","author":"S Appunni","year":"2021","unstructured":"Appunni, S. et al. Biglycan: an emerging small leucine-rich proteoglycan (SLRP) marker and its clinicopathological significance. Mol. Cell. Biochem. 476, 3935\u20133950 (2021).","journal-title":"Mol. Cell. Biochem."},{"key":"44986_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cytogfr.2020.05.009","volume":"53","author":"EO Gubernatorova","year":"2020","unstructured":"Gubernatorova, E. O., Gorshkova, E. A., Polinova, A. I. & Drutskaya, M. S. IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 53, 13\u201324 (2020).","journal-title":"Cytokine Growth Factor Rev."},{"key":"44986_CR22","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.addr.2003.08.002","volume":"55","author":"K Gelse","year":"2003","unstructured":"Gelse, K., P\u00f6schl, E. & Aigner, T. Collagens-structure, function, and biosynthesis. Adv. Drug Deliv. Rev. 55, 1531\u20131546 (2003).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"44986_CR23","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.biocel.2006.10.008","volume":"39","author":"MP Crippa","year":"2007","unstructured":"Crippa, M. P. Urokinase-type plasminogen activator. Int. J. Biochem. Cell Biol. 39, 690\u2013694 (2007).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"44986_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0945-053X(00)00104-9","volume":"19","author":"P Bornstein","year":"2000","unstructured":"Bornstein, P., Armstrong, L. C., Hankenson, K. D., Kyriakides, T. R. & Yang, Z. Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol. 19, 557\u2013568 (2000).","journal-title":"Matrix Biol."},{"key":"44986_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.matbio.2018.03.005","volume":"73","author":"Y Zhou","year":"2018","unstructured":"Zhou, Y. et al. Extracellular matrix in lung development, homeostasis and disease. Matrix Biol. 73, 77\u2013104 (2018).","journal-title":"Matrix Biol."},{"key":"44986_CR26","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.bbagen.2014.01.013","volume":"1840","author":"NE Calabro","year":"2014","unstructured":"Calabro, N. E., Kristofik, N. J. & Kyriakides, T. R. Thrombospondin-2 and extracellular matrix assembly. Biochim. Biophys. Acta 1840, 2396\u20132402 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"44986_CR27","doi-asserted-by":"publisher","unstructured":"Xia, L. et al. A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19. Cell. Mol. Immunol. 1\u201314 https:\/\/doi.org\/10.1038\/s41423-023-00985-3 (2023).","DOI":"10.1038\/s41423-023-00985-3"},{"key":"44986_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-021-03570-8","volume":"595","author":"TM Delorey","year":"2021","unstructured":"Delorey, T. M. et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature 595, 107\u2013113 (2021).","journal-title":"Nature"},{"key":"44986_CR29","doi-asserted-by":"publisher","first-page":"27621","DOI":"10.1074\/jbc.M510507200","volume":"281","author":"MM Sullivan","year":"2006","unstructured":"Sullivan, M. M. et al. Matricellular hevin regulates decorin production and collagen assembly. J. Biol. Chem. 281, 27621\u201327632 (2006).","journal-title":"J. Biol. Chem."},{"key":"44986_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98253-9","volume":"11","author":"Y Kimura","year":"2021","unstructured":"Kimura, Y. et al. Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach. Sci. Rep. 11, 20638 (2021).","journal-title":"Sci. Rep."},{"key":"44986_CR31","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1021\/acs.jproteome.1c00054","volume":"20","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Proteomic analysis identifies prolonged disturbances in pathways related to cholesterol metabolism and myocardium function in the COVID-19 recovery stge. J. Proteome Res. 20, 3463\u20133474 (2021).","journal-title":"J. Proteome Res."},{"key":"44986_CR32","doi-asserted-by":"publisher","first-page":"e2200070","DOI":"10.1002\/prca.202200070","volume":"17","author":"AT Sahin","year":"2023","unstructured":"Sahin, A. T. et al. Plasma proteomics identify potential severity biomarkers from COVID-19 associated network. Proteom. Clin. Appl. 17, e2200070 (2023).","journal-title":"Proteom. Clin. Appl."},{"key":"44986_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s10875-022-01386-3","volume":"43","author":"T Ebihara","year":"2023","unstructured":"Ebihara, T. et al. Combination of WFDC2, CHI3L1, and KRT19 in plasma defines a clinically useful molecular phenotype associated with prognosis in critically ill COVID-19. Patients. J. Clin. Immunol. 43, 286\u2013298 (2023).","journal-title":"Patients. J. Clin. Immunol."},{"key":"44986_CR34","doi-asserted-by":"publisher","first-page":"e632","DOI":"10.1016\/S2589-7500(22)00112-1","volume":"4","author":"SK Byeon","year":"2022","unstructured":"Byeon, S. K. et al. Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study. Lancet. Digit. Heal. 4, e632\u2013e645 (2022).","journal-title":"Lancet. Digit. Heal."},{"key":"44986_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28639-4","volume":"13","author":"MAY Al-Nesf","year":"2022","unstructured":"Al-Nesf, M. A. Y. et al. Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nat. Commun. 13, 946 (2022).","journal-title":"Nat. Commun."},{"key":"44986_CR36","doi-asserted-by":"publisher","first-page":"100779","DOI":"10.1016\/j.xcrm.2022.100779","volume":"3","author":"TJ LaSalle","year":"2022","unstructured":"LaSalle, T. J. et al. Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients. Cell Rep. Med. 3, 100779 (2022).","journal-title":"Cell Rep. Med."},{"key":"44986_CR37","doi-asserted-by":"publisher","unstructured":"Ahern, D. J. et al. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell https:\/\/doi.org\/10.1016\/j.cell.2022.01.012 (2022).","DOI":"10.1016\/j.cell.2022.01.012"},{"key":"44986_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/jcmm.17622","volume":"27","author":"C Iosef","year":"2023","unstructured":"Iosef, C. et al. COVID-19 plasma proteome reveals novel temporal and cell-specific signatures for disease severity and high-precision disease management. J. Cell. Mol. Med. 27, 141\u2013157 (2023).","journal-title":"J. Cell. Mol. Med."},{"key":"44986_CR39","doi-asserted-by":"publisher","first-page":"100680","DOI":"10.1016\/j.xcrm.2022.100680","volume":"3","author":"D Feyaerts","year":"2022","unstructured":"Feyaerts, D. et al. Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19. Cell Rep. Med. 3, 100680 (2022).","journal-title":"Cell Rep. Med."},{"key":"44986_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85877-0","volume":"11","author":"H Patel","year":"2021","unstructured":"Patel, H. et al. Proteomic blood profiling in mild, severe and critical COVID-19 patients. Sci. Rep. 11, 6357 (2021).","journal-title":"Sci. Rep."},{"key":"44986_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cels.2020.05.012","volume":"11","author":"CB Messner","year":"2020","unstructured":"Messner, C. B. et al. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst. 11, 11\u201324.e4 (2020).","journal-title":"Cell Syst."},{"key":"44986_CR42","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.immuni.2020.10.008","volume":"53","author":"T Shu","year":"2020","unstructured":"Shu, T. et al. Plasma proteomics identify biomarkers and pathogenesis of COVID-19. Immunity 53, 1108\u20131122.e5 (2020).","journal-title":"Immunity"},{"key":"44986_CR43","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.2147\/JIR.S322430","volume":"14","author":"A Alaiya","year":"2021","unstructured":"Alaiya, A. et al. Alterations in the plasma proteome induced by SARS-CoV-2 and MERS-CoV reveal biomarkers for disease outcomes for COVID-19 patients. J. Inflamm. Res. 14, 4313\u20134328 (2021).","journal-title":"J. Inflamm. Res."},{"key":"44986_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77525-w","volume":"10","author":"L Haljasm\u00e4gi","year":"2020","unstructured":"Haljasm\u00e4gi, L. et al. Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19. Sci. Rep. 10, 20533 (2020).","journal-title":"Sci. Rep."},{"key":"44986_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/thx.42.1.1","volume":"42","author":"MP Barrowcliffe","year":"1987","unstructured":"Barrowcliffe, M. P. & Jones, J. G. Solute permeability of the alveolar capillary barrier. Thorax 42, 1\u201310 (1987).","journal-title":"Thorax"},{"key":"44986_CR46","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1165\/rcmb.2013-0541RT","volume":"50","author":"F Rezaee","year":"2014","unstructured":"Rezaee, F. & Georas, S. N. Breaking barriers. New insights into airway epithelial barrier function in health and disease. Am. J. Respir. Cell Mol. Biol. 50, 857\u2013869 (2014).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"44986_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03594-6","volume":"25","author":"R Shi","year":"2021","unstructured":"Shi, R. et al. COVID-19 ARDS is characterized by higher extravascular lung water than non-COVID-19 ARDS: the PiCCOVID study. Crit. Care 25, 186 (2021).","journal-title":"Crit. Care"},{"key":"44986_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s43556-021-00031-6","volume":"2","author":"X Liu","year":"2021","unstructured":"Liu, X., Fang, Y., Noble, P. W., Que, J. & Jiang, D. Disruption of respiratory epithelial basement membrane in COVID-19 patients. Mol. Biomed. 2, 8 (2021).","journal-title":"Mol. Biomed."},{"key":"44986_CR49","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1056\/NEJMc1711824","volume":"377","author":"BT Thompson","year":"2017","unstructured":"Thompson, B. T., Chambers, R. C. & Liu, K. D. Acute respiratory distress syndrome. N. Engl. J. Med. 377, 1904\u20131905, https:\/\/doi.org\/10.1056\/NEJMc1711824 (2017).","journal-title":"N. Engl. J. Med."},{"key":"44986_CR50","doi-asserted-by":"publisher","first-page":"e69314","DOI":"10.7554\/eLife.69314","volume":"10","author":"R Rauti","year":"2021","unstructured":"Rauti, R. et al. Effect of SARS-CoV-2 proteins on vascular permeability. Elife 10, e69314 (2021).","journal-title":"Elife"},{"key":"44986_CR51","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 383, 120\u2013128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"44986_CR52","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1164\/rccm.202107-1774OC","volume":"206","author":"J Joffre","year":"2022","unstructured":"Joffre, J. et al. COVID-19-associated lung microvascular endotheliopathy: a \u2018From the Bench\u2019 perspective. Am. J. Respir. Crit. Care Med. 206, 961\u2013972 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"44986_CR53","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1183\/09031936.00196412","volume":"43","author":"EL Burnham","year":"2014","unstructured":"Burnham, E. L., Janssen, W. J., Riches, D. W. H., Moss, M. & Downey, G. P. The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur. Respir. J. 43, 276\u2013285 (2014).","journal-title":"Eur. Respir. J."},{"key":"44986_CR54","doi-asserted-by":"publisher","first-page":"1054690","DOI":"10.3389\/fcvm.2022.1054690","volume":"9","author":"LM Arguinchona","year":"2022","unstructured":"Arguinchona, L. M., Zagona-Prizio, C., Joyce, M. E., Chan, E. D. & Maloney, J. P. Microvascular significance of TGF-\u03b2 axis activation in COVID-19. Front. Cardiovasc. Med. 9, 1054690 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"44986_CR55","doi-asserted-by":"publisher","first-page":"120703","DOI":"10.1016\/j.lfs.2022.120703","volume":"304","author":"A Gupta","year":"2022","unstructured":"Gupta, A. et al. SARS-CoV-2 infection-induced growth factors play differential roles in COVID-19 pathogenesis. Life Sci. 304, 120703 (2022).","journal-title":"Life Sci."},{"key":"44986_CR56","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cytogfr.2021.09.002","volume":"62","author":"L Yang","year":"2021","unstructured":"Yang, L. et al. FGF\/FGFR signaling: from lung development to respiratory diseases. Cytokine Growth Factor Rev. 62, 94\u2013104 (2021).","journal-title":"Cytokine Growth Factor Rev."},{"key":"44986_CR57","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.cell.2011.10.003","volume":"147","author":"B-S Ding","year":"2011","unstructured":"Ding, B.-S. et al. Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell 147, 539\u2013553 (2011).","journal-title":"Cell"},{"key":"44986_CR58","doi-asserted-by":"publisher","first-page":"e1010228","DOI":"10.1371\/journal.ppat.1010228","volume":"18","author":"BE Hiller","year":"2022","unstructured":"Hiller, B. E. et al. Fibroblast growth factor-9 expression in airway epithelial cells amplifies the type I interferon response and alters influenza A virus pathogenesis. PLoS Pathog. 18, e1010228 (2022).","journal-title":"PLoS Pathog."},{"key":"44986_CR59","doi-asserted-by":"publisher","unstructured":"Yao, C. et al. Maladaptive TGF-\u03b2 signals to the alveolar epithelium drive fibrosis after COVID-19 infection. Am. J. Respir. Crit. Care Med. 208, 201\u2013204. https:\/\/doi.org\/10.1164\/rccm.202302-0264LE (2023).","DOI":"10.1164\/rccm.202302-0264LE"},{"key":"44986_CR60","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.drudis.2020.06.013","volume":"25","author":"D D\u2019Alonzo","year":"2020","unstructured":"D\u2019Alonzo, D., De Fenza, M. & Pavone, V. COVID-19 and pneumonia: a role for the uPA\/uPAR system. Drug Discov. Today 25, 1528\u20131534 (2020).","journal-title":"Drug Discov. Today"},{"key":"44986_CR61","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1165\/rcmb.2010-0302OC","volume":"45","author":"T Nassar","year":"2011","unstructured":"Nassar, T. et al. Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice. Am. J. Respir. Cell Mol. Biol. 45, 1015\u20131021 (2011).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"44986_CR62","doi-asserted-by":"publisher","first-page":"C589","DOI":"10.1152\/ajpcell.00235.2017","volume":"314","author":"H Alsaffar","year":"2018","unstructured":"Alsaffar, H., Martino, N., Garrett, J. P. & Adam, A. P. Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis. Am. J. Physiol. Cell Physiol. 314, C589\u2013C602 (2018).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"44986_CR63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/bioengineering8010013","volume":"8","author":"L Liu","year":"2021","unstructured":"Liu, L., Stephens, B., Bergman, M., May, A. & Chiang, T. Role of collagen in airway mechanics. Bioengineering 8, 13 (2021).","journal-title":"Bioengineering"},{"key":"44986_CR64","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/jcb.25721","volume":"118","author":"T Hara","year":"2017","unstructured":"Hara, T. et al. Biglycan intensifies ALK5-Smad2\/3 signaling by TGF-\u03b2(1) and downregulates syndecan-4 in cultured vascular endothelial cells. J. Cell. Biochem. 118, 1087\u20131096 (2017).","journal-title":"J. Cell. Biochem."},{"key":"44986_CR65","doi-asserted-by":"publisher","first-page":"a022053","DOI":"10.1101\/cshperspect.a022053","volume":"8","author":"C-H Heldin","year":"2016","unstructured":"Heldin, C.-H. & Moustakas, A. Signaling receptors for TGF-\u03b2 family members. Cold Spring Harb. Perspect. Biol 8, a022053 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol"},{"key":"44986_CR66","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1161\/CIRCULATIONAHA.112.134304","volume":"126","author":"J Aman","year":"2012","unstructured":"Aman, J. et al. Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation 126, 2728\u20132738 (2012).","journal-title":"Circulation"},{"key":"44986_CR67","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1161\/ATVBAHA.115.305085","volume":"35","author":"AN Rizzo","year":"2015","unstructured":"Rizzo, A. N., Aman, J., van Nieuw Amerongen, G. P. & Dudek, S. M. Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome. Arterioscler. Thromb. Vasc. Biol. 35, 1071\u20131079 (2015).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"44986_CR68","doi-asserted-by":"publisher","first-page":"L259","DOI":"10.1152\/ajplung.00323.2014","volume":"308","author":"E Letsiou","year":"2015","unstructured":"Letsiou, E. et al. Differential and opposing effects of imatinib on {LPS}- and ventilator-induced lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L259\u2013L269 (2015).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"44986_CR69","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10753-017-0659-5","volume":"41","author":"OS Zaki","year":"2018","unstructured":"Zaki, O. S., Safar, M. M., Ain-Shoka, A. A. & Rashed, L. A. A novel role of a chemotherapeutic agent in a rat model of endotoxemia: modulation of the STAT-3 signaling pathway. Inflammation 41, 20\u201332 (2018).","journal-title":"Inflammation"},{"key":"44986_CR70","doi-asserted-by":"publisher","first-page":"L866","DOI":"10.1152\/ajplung.00006.2022","volume":"322","author":"Y Xin","year":"2022","unstructured":"Xin, Y. et al. Imatinib alleviates lung injury and prolongs survival in ventilated rats. Am. J. Physiol. Lung Cell. Mol. Physiol. 322, L866\u2013L872 (2022).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"44986_CR71","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cmet.2022.01.008","volume":"34","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. Cell Metab. 34, 424\u2013440.e7 (2022).","journal-title":"Cell Metab."},{"key":"44986_CR72","doi-asserted-by":"publisher","first-page":"105137","DOI":"10.1016\/j.antiviral.2021.105137","volume":"193","author":"F Touret","year":"2021","unstructured":"Touret, F. et al. Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2. Antiviral Res. 193, 105137 (2021).","journal-title":"Antiviral Res."},{"key":"44986_CR73","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1177\/0960327116681649","volume":"36","author":"El-AgamyDS.","year":"2017","unstructured":"El-AgamyDS. Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits. Hum. Exp. Toxicol. 36, 1131\u20131145 (2017).","journal-title":"Hum. Exp. Toxicol."},{"key":"44986_CR74","doi-asserted-by":"publisher","first-page":"e10426","DOI":"10.15252\/msb.202110426","volume":"17","author":"M Chan","year":"2021","unstructured":"Chan, M. et al. Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release. Mol. Syst. Biol. 17, e10426 (2021).","journal-title":"Mol. Syst. Biol."},{"key":"44986_CR75","doi-asserted-by":"publisher","first-page":"jcs240077","DOI":"10.1242\/jcs.240077","volume":"133","author":"L Botros","year":"2020","unstructured":"Botros, L. et al. Bosutinib prevents vascular leakage by reducing focal adhesion turnover and reinforcing junctional integrity. J. Cell Sci. 133, jcs240077 (2020).","journal-title":"J. Cell Sci."},{"key":"44986_CR76","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12950-020-00261-5","volume":"17","author":"JG Macfarlane","year":"2020","unstructured":"Macfarlane, J. G. et al. Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury. J. Inflamm. 17, 34 (2020).","journal-title":"J. Inflamm."},{"key":"44986_CR77","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.molmed.2005.07.007","volume":"11","author":"M Mohty","year":"2005","unstructured":"Mohty, M., Blaise, D., Olive, D. & Gaugler, B. Imatinib: the narrow line between immune tolerance and activation. Trends Mol. Med. 11, 397\u2013402 (2005).","journal-title":"Trends Mol. Med."},{"key":"44986_CR78","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1002\/jcp.23029","volume":"227","author":"R Ciarcia","year":"2012","unstructured":"Ciarcia, R. et al. Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. J. Cell. Physiol. 227, 2798\u20132803 (2012).","journal-title":"J. Cell. Physiol."},{"key":"44986_CR79","doi-asserted-by":"publisher","first-page":"2000279","DOI":"10.1183\/13993003.00279-2020","volume":"56","author":"J Weatherald","year":"2020","unstructured":"Weatherald, J. et al. Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. Eur. Respir. J. 56, 2000279 (2020).","journal-title":"Eur. Respir. J."},{"key":"44986_CR80","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi, J. J. & Deininger, M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J. Clin. Oncol. 33, 4210\u20134218 (2015).","journal-title":"J. Clin. Oncol."},{"key":"44986_CR81","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10428194.2018.1466294","volume":"60","author":"A Gover-Proaktor","year":"2019","unstructured":"Gover-Proaktor, A. et al. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. Leuk. Lymphoma 60, 189\u2013199 (2019).","journal-title":"Leuk. Lymphoma"},{"key":"44986_CR82","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3389\/fphar.2020.01007","volume":"11","author":"H Haguet","year":"2020","unstructured":"Haguet, H. et al. The risk of arterial thrombosis in patients with chronic myeloid leukemia treated with second and third generation BCR-ABL tyrosine kinase inhibitors may be explained by their impact on endothelial cells: an in-vitro study. Front. Pharmacol. 11, 1007 (2020).","journal-title":"Front. Pharmacol."},{"key":"44986_CR83","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1172\/JCI86249","volume":"126","author":"C Guignabert","year":"2016","unstructured":"Guignabert, C. et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J. Clin. Investig. 126, 3207\u20133218 (2016).","journal-title":"J. Clin. Investig."},{"key":"44986_CR84","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fcvm.2018.00125","volume":"5","author":"J Paez-Mayorga","year":"2018","unstructured":"Paez-Mayorga, J. et al. Ponatinib activates an inflammatory response in endothelial cells via ERK5 SUMOylation. Front. Cardiovasc. Med. 5, 125 (2018).","journal-title":"Front. Cardiovasc. Med."},{"key":"44986_CR85","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2015","unstructured":"Valent, P. et al. Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood 125, 901\u2013906 (2015).","journal-title":"Blood"},{"key":"44986_CR86","doi-asserted-by":"publisher","unstructured":"Duijvelaar, E. et al. Cardiac safety of imatinib for the treatment of Covid-19: a secondary analysis of a randomised, double blind, placebo-controlled trial. J. Cardiovasc. Pharmacol. https:\/\/doi.org\/10.1097\/FJC.0000000000001344 (2022).","DOI":"10.1097\/FJC.0000000000001344"},{"key":"44986_CR87","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/sj.leu.2404207","volume":"20","author":"K Ohnishi","year":"2006","unstructured":"Ohnishi, K., Sakai, F., Kudoh, S. & Ohno, R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 20, 1162\u20131164, https:\/\/doi.org\/10.1038\/sj.leu.2404207 (2006).","journal-title":"Leukemia"},{"key":"44986_CR88","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1365-2141.2004.04833.x","volume":"125","author":"I Isshiki","year":"2004","unstructured":"Isshiki, I., Yamaguchi, K. & Okamoto, S. Interstitial pneumonitis during imatinib therapy. Br. J. Haematol. 125, 420 (2004).","journal-title":"Br. J. Haematol."},{"key":"44986_CR89","doi-asserted-by":"publisher","first-page":"e14402","DOI":"10.1097\/MD.0000000000014402","volume":"98","author":"P Zhang","year":"2019","unstructured":"Zhang, P., Huang, J., Jin, F., Pan, J. & Ouyang, G. Imatinib-induced irreversible interstitial lung disease: a case report. Medicine 98, e14402 (2019).","journal-title":"Medicine"},{"key":"44986_CR90","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1200\/JCO.2003.03.037","volume":"21","author":"MF Rosado","year":"2003","unstructured":"Rosado, M. F., Donna, E. & Ahn, Y. S. Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis. J. Clin. Oncol. 21, 3171\u20133173 (2003).","journal-title":"J. Clin. Oncol."},{"key":"44986_CR91","unstructured":"UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 49, D480\u2013D489 (2021)."},{"key":"44986_CR92","doi-asserted-by":"publisher","first-page":"eabm5164","DOI":"10.1126\/sciadv.abm5164","volume":"8","author":"DH Katz","year":"2022","unstructured":"Katz, D. H. et al. Proteomic profiling platforms head to head: leveraging genetics and clinical traits to compare aptamer- and antibody-based methods. Sci. Adv. 8, eabm5164 (2022).","journal-title":"Sci. Adv."},{"key":"44986_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27164-0","volume":"12","author":"M Pietzner","year":"2021","unstructured":"Pietzner, M. et al. Synergistic insights into human health from aptamer- and antibody-based proteomic profiling. Nat. Commun. 12, 6822 (2021).","journal-title":"Nat. Commun."},{"key":"44986_CR94","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41588-022-01051-w","volume":"54","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat. Genet. 54, 593\u2013602 (2022).","journal-title":"Nat. Genet."},{"key":"44986_CR95","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","volume":"53","author":"E Ferkingstad","year":"2021","unstructured":"Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and disease. Nat. Genet. 53, 1712\u20131721 (2021).","journal-title":"Nat. Genet."},{"key":"44986_CR96","doi-asserted-by":"publisher","first-page":"eabj1541","DOI":"10.1126\/science.abj1541","volume":"374","author":"M Pietzner","year":"2021","unstructured":"Pietzner, M. et al. Mapping the proteo-genomic convergence of human diseases. Science 374, eabj1541 (2021).","journal-title":"Science"},{"key":"44986_CR97","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13195-022-01113-5","volume":"14","author":"EB Dammer","year":"2022","unstructured":"Dammer, E. B. et al. Multi-platform proteomic analysis of Alzheimer\u2019s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome. Alzheimers. Res. Ther. 14, 174 (2022).","journal-title":"Alzheimers. Res. Ther."},{"key":"44986_CR98","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1126\/science.aaq1327","volume":"361","author":"V Emilsson","year":"2018","unstructured":"Emilsson, V. et al. Co-regulatory networks of human serum proteins link genetics to disease. Science 361, 769\u2013773 (2018).","journal-title":"Science"},{"key":"44986_CR99","doi-asserted-by":"publisher","first-page":"e1900278","DOI":"10.1002\/pmic.201900278","volume":"20","author":"LM Raffield","year":"2020","unstructured":"Raffield, L. M. et al. Comparison of proteomic assessment methods in multiple cohort studies. Proteomics 20, e1900278 (2020).","journal-title":"Proteomics"},{"key":"44986_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05512-x","volume":"9","author":"C Yao","year":"2018","unstructured":"Yao, C. et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat. Commun. 9, 3268 (2018).","journal-title":"Nat. Commun."},{"key":"44986_CR101","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1136\/thoraxjnl-2020-216256","volume":"76","author":"A Saris","year":"2021","unstructured":"Saris, A. et al. Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19. Thorax 76, 1010\u20131019 (2021).","journal-title":"Thorax"},{"key":"44986_CR102","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13054-021-03513-9","volume":"25","author":"Y Jouan","year":"2021","unstructured":"Jouan, Y., Baranek, T., Si-Tahar, M., Paget, C. & Guillon, A. Lung compartmentalization of inflammatory biomarkers in COVID-19-related ARDS. Critical Care 25, 120, https:\/\/doi.org\/10.1186\/s13054-021-03513-9 (2021).","journal-title":"Critical Care"},{"key":"44986_CR103","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1136\/thorax-2023-219989","volume":"78","author":"J de Brabander","year":"2023","unstructured":"de Brabander, J. et al. Persistent alveolar inflammatory response in critically ill patients with COVID-19 is associated with mortality. Thorax 78, 912\u2013921 (2023).","journal-title":"Thorax"},{"key":"44986_CR104","doi-asserted-by":"publisher","first-page":"626553","DOI":"10.3389\/fmicb.2021.626553","volume":"12","author":"S Shou","year":"2021","unstructured":"Shou, S. et al. Animal models for COVID-19: hamsters, mouse, ferret, mink, tree shrew, and non-human primates. Front. Microbiol. 12, 626553 (2021).","journal-title":"Front. Microbiol."},{"key":"44986_CR105","doi-asserted-by":"publisher","first-page":"E374","DOI":"10.1073\/pnas.1306798111","volume":"111","author":"DM Peters","year":"2014","unstructured":"Peters, D. M. et al. TGF-\u03b2 directs trafficking of the epithelial sodium channel ENaC which has implications for ion and fluid transport in acute lung injury. Proc. Natl. Acad. Sci. USA. 111, E374\u2013E383 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"44986_CR106","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(22)01485-4","volume":"400","author":"LDJ Bos","year":"2022","unstructured":"Bos, L. D. J. & Ware, L. B. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. Lancet 400, 1145\u20131156 (2022).","journal-title":"Lancet"},{"key":"44986_CR107","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1165\/rcmb.2021-0091TR","volume":"65","author":"AS Ambade","year":"2021","unstructured":"Ambade, A. S., Hassoun, P. M. & Damico, R. L. Basement membrane extracellular matrix proteins in pulmonary vascular and right ventricular remodeling in pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 65, 245\u2013258 (2021).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"44986_CR108","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1164\/rccm.202105-1118OC","volume":"205","author":"CJ Rhodes","year":"2022","unstructured":"Rhodes, C. J. et al. Using the plasma proteome for risk stratifying patients with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 205, 1102\u20131111 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"44986_CR109","doi-asserted-by":"publisher","first-page":"106418","DOI":"10.1016\/j.ejps.2023.106418","volume":"184","author":"N Baalbaki","year":"2023","unstructured":"Baalbaki, N. et al. Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19. Eur. J. Pharm. Sci. 184, 106418 (2023).","journal-title":"Eur. J. Pharm. Sci."},{"key":"44986_CR110","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/psp4.12718","volume":"10","author":"IH Bartelink","year":"2021","unstructured":"Bartelink, I. H. et al. Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: lessons from the CounterCOVID - imatinib study. CPT Pharmacomet. Syst. Pharmacol 10, 1497\u20131511 (2021).","journal-title":"CPT Pharmacomet. Syst. Pharmacol"},{"key":"44986_CR111","unstructured":"The SomaScan Platform - Our Science - Platform - SomaLogic. https:\/\/somalogic.com\/somascan-platform\/."},{"key":"44986_CR112","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/bioinformatics\/btw777","volume":"33","author":"DJ McCarthy","year":"2017","unstructured":"McCarthy, D. J., Campbell, K. R., Lun, A. T. L. & Wills, Q. F. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179\u20131186 (2017).","journal-title":"Bioinformatics"},{"key":"44986_CR113","doi-asserted-by":"publisher","first-page":"e0191629","DOI":"10.1371\/journal.pone.0191629","volume":"13","author":"LC Gandolfo","year":"2018","unstructured":"Gandolfo, L. C. & Speed, T. P. RLE plots: Visualizing unwanted variation in high dimensional data. PLoS One 13, e0191629 (2018).","journal-title":"PLoS One"},{"key":"44986_CR114","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nbt0308-303","volume":"26","author":"M Ringn\u00e9r","year":"2008","unstructured":"Ringn\u00e9r, M. What is principal component analysis? Nat. Biotechnol. 26, 303\u2013304 (2008).","journal-title":"Nat. Biotechnol."},{"key":"44986_CR115","first-page":"1","volume":"82","author":"A Kuznetsova","year":"2017","unstructured":"Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. B. lmerTest Package: tests in linear mixed. Effects Models. J. Stat. Softw. 82, 1\u201326 (2017).","journal-title":"Effects Models. J. Stat. Softw."},{"key":"44986_CR116","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3389\/fgene.2019.00858","volume":"10","author":"E Ulgen","year":"2019","unstructured":"Ulgen, E., Ozisik, O. & Sezerman, O. U. pathfindR: an R package for comprehensive identification of enriched pathways in omics data through active subnetworks. Front. Genet. 10, 858 (2019).","journal-title":"Front. Genet."},{"key":"44986_CR117","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"44986_CR118","doi-asserted-by":"publisher","first-page":"D535","DOI":"10.1093\/nar\/gkj109","volume":"34","author":"C Stark","year":"2006","unstructured":"Stark, C. et al. BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 34, D535\u2013D539 (2006).","journal-title":"Nucleic Acids Res."},{"key":"44986_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1\u201322 (2010).","journal-title":"J. Stat. Softw."},{"key":"44986_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v028.i05","volume":"28","author":"M Kuhn","year":"2008","unstructured":"Kuhn, M. Building predictive models in R using the caret package. J. Stat. Softw. 28, 1\u201326 (2008).","journal-title":"J. Stat. Softw."},{"key":"44986_CR121","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44986-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44986-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44986-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T09:07:04Z","timestamp":1706173624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44986-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["44986"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-44986-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2872132\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"28 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.A. is a co-inventor of a patent (WO2012150857A1, 2011) covering protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase Abl-related gene (Arg). All other authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"744"}}